FRANKFURT, Oct 12 (Reuters) - Curevac said it would
not have to pay back the 450 million euros ($520 million) it
received from the European Union as part of an advance
purchasing agreement of COVID-19 vaccines because the funding
was not contingent on delivery of doses.
Chief Executive Franz-Werner Haas said in a news conference
on Tuesday that the EU payment was non-refundable.
The German biotech firm earlier on Tuesday abandoned a
request for regulatory approval of its first-generation COVID-19
vaccine candidate and will instead focus on collaborating with
GSK to develop second-generation mRNA vaccine
technology.
($1 = 0.8663 euros)
(Reporting by Ludwig Burger and Christina Amann; Editing by
Maria Sheahan)